Steward of the Early Biological Response Decision Protocol
Advancing early-stage R&D from commitment bias
to disciplined capital governance.
We do not predict success.
We govern commitment when outcomes are not yet visible.
The Capital Escalation Gap
In modeled early-stage scenarios, a biological signal becomes available before governance action. During this interval, capital commitment may continue to escalate.
Figure 1.1: The Capital Escalation Gap (Illustrative Scenario Model).
In modeled early-stage scenarios, the majority of capital commitment continues to escalate after an early biological signal becomes available — illustrating the structural governance gap the EBR Protocol is designed to address.
Source: EBR scenario modeling (illustrative; not derived from empirical historical datasets).
Structure
The EBR ecosystem is intentionally structured to separate standard, stewardship, and implementation. Each component serves a distinct role.
The canonical definition of the Early Biological Response Decision Protocol — a non-predictive methodology for early biological decision governance.
ebrprotocol.org →The organizational steward responsible for protocol definition and versioning, governance principles, and evidence standards. The Institute does not sell products or consulting services.
ebrinstitute.org →Operational applications of EBR-compliant decision reviews, including structured early decision audits. No implementation defines or modifies the protocol.
ebrprotocol.com →Frameworks for integration with pharma, biotech, and investment governance structures. Designed for institutional-grade R&D oversight.
ebrinstitute.com →The Problem
Early-stage R&D is rarely limited by lack of data. It is limited by how long decisions remain unmade.
The governance gap emerges when capital commitment continues after decision-relevant signals become available.
Commitment often persists well beyond the point where decision-relevant signals are already present — driven by organizational inertia, sunk cost bias, and delayed governance.
Capital escalation frequently continues after biological commitment has already failed to materialize. This gap can be systematically addressed through explicit decision governance.
The EBR Protocol
The Early Biological Response Decision Protocol is a governance standard for early-stage biological decision-making under uncertainty. It is non-predictive by design.
The protocol does not estimate probabilities or future outcomes. Decisions are bounded to evidence present within the early commitment window.
Decisions are made strictly on evidence available within the early commitment window — no extrapolation, no narrative override.
Every decision resolves to one of three outcomes. The protocol governs when commitment is justified — not whether outcomes will succeed.
Evidence Stack
The EBR Protocol is supported by structured scenario modeling across constructed early-stage R&D archetypes. Detailed materials are available upon request under NDA.
Advisory & Stewardship
The EBR Institute is establishing a fellowship of senior industry leaders, former executives, and biomedical scientists to support the development and governance of the EBR Protocol.
The profiles below reflect the intended composition of the institute, based on required expertise across pharma R&D, translational science, and capital allocation.
Initial discussions with potential contributors are ongoing. Formal appointments will be announced upon institute formalization.
Participation is based on stewardship, not endorsement.
Interested in contributing to the EBR Fellowship?
Request Access to Learn MoreInstitutional Positioning